• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Life sciences >ATRIAL NATRIURETIC PEPTIDE INCREASES ADRENOMEDULLIN IN THE CIRCULATION OF HEALTHY HUMANS
【24h】

ATRIAL NATRIURETIC PEPTIDE INCREASES ADRENOMEDULLIN IN THE CIRCULATION OF HEALTHY HUMANS

机译：心钠素在健康人的循环中增加肾上腺素

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Adrenomedullin (ADM) is a new 52 amino acid peptide originally isolated from extracts of human pheochromocytoma. ADM's biologic properties are nearly identical to those of atrial natriuretic peptides. Thus, the 4 peptide hormones originating from amino acids 1-30 [long acting natriuretic peptide], 31-67 [vessel dilator], 79-98 [kaliuretic peptide] and 99-126 [atrial natriuretic factor; ANF] of the 126 amino acid ANF prohormone as well as ADM have blood pressure lowering and diuretic properties. The present investigation was designed to determine if one or more of these 4 atrial natriuretic peptides increase adrenomedullin within the circulation of healthy humans. Infusion of 100 ng/kg body weight/minute for 60 minutes of the respective atrial peptides resulted in a 4-fold (P<0.001) increase in the circulating concentration of adrenomedullin secondary to the ANF infusion but no increase in adrenomedullin with the long acting natriuretic peptide, vessel dilator, or kaliuretic peptide infusions. The four-fold increase of adrenomedullin in the circulation persisted throughout the infusion of ANF, but returned to pre-infusion levels within 30 minutes of stopping the ANF infusion. Infusion of 10 pg/kg body weight/minute for 60 minutes of ANF resulted ina 2 1/2-fold increase (P<0.05) in the circulating concentration of adrenomedullin. There was a significant (P<0.01) diuresis and blood pressure lowering effect with each of the atrial natriuretic peptides in the present investigation. This investigation suggests that 1) atrial natriuretic factor increases the release of adrenomedullin and 2) that the diuretic and blood pressure lowering effects previously attributed to atrial natriuretic factor may be partially due to adrenomedullin since both increased during the ANF infusion and both have similar biologic effects. As opposed to atrial natriuretic factor, adrenomedullin was not increased by long acting natriuretic peptide, vessel dilator, or kaliuretic peptide suggesting that their biologic effects do not involve adrenomedullin. [References: 30]
机译：肾上腺髓质素（ADM）是一种新的52个氨基酸的肽，最初是从人类嗜铬细胞瘤提取物中分离出来的。 ADM的生物学特性几乎与心钠素相同。因此，源自氨基酸1-30 [长效利钠肽]，31-67 [血管扩张剂]，79-98 [钾利尿肽]和99-126 [心钠素]的4种肽激素。 126个氨基酸的ANF激素和ADM具有降血压和利尿作用。本研究旨在确定这四种心房利钠肽中的一种或多种是否会增加健康人体内的肾上腺髓质素。在60分钟内以100 ng / kg体重/分钟的速度输注各自的心房肽导致ANF输注后肾上腺髓质的循环浓度增加4倍（P <0.001），但长效时肾上腺髓质素没有增加利钠肽，血管扩张剂或利尿肽输注。整个ANF输注过程中，肾上腺髓质素增加了四倍，但在停止ANF输注后30分钟内恢复到输注前水平。以10 pg / kg体重/分钟的速度输注60分钟的ANF可使肾上腺髓质素的循环浓度增加2 1/2倍（P <0.05）。在本研究中，每种心房利钠肽均具有显着的（P <0.01）利尿和降血压作用。这项研究表明，1）心钠素的释放增加了肾上腺髓质素的释放，2）先前归因于心钠素的利尿和​​血压降低的作用可能部分归因于肾上腺髓质素，因为两者在ANF输注过程中均增加并且具有相似的生物学作用。 。与心钠素相反，长效利钠肽，血管扩张剂或利尿钠肽不会增加肾上腺髓质素的水平，表明它们的生物学作用不涉及肾上腺髓质素。 [参考：30]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号